<DOC>
	<DOCNO>NCT02563106</DOCNO>
	<brief_summary>A Phase 2b Parallel-Group , Double-Blind , Placebo-Controlled , Multicenter Study SYN-004 Compared Placebo Prevention Clostridium difficile Infection ( CDI ) Hospitalized Patients receive IV ceftriaxone Diagnosis Lower Respiratory Tract Infection ( LRTI ) .</brief_summary>
	<brief_title>A Study SYN-004 Prevention C.Diff Patients With LRTI</brief_title>
	<detailed_description>This Phase 2b , randomize , double-blind , placebo control , parallel-group , multi-center proof-of-concept study assess potential SYN-004 prevention CDI unwanted side effect IV antibiotic treatment risk patient hospitalize LRTI receive IV ceftriaxone alone combination macrolide . Subjects 50 year old . The entire duration study may 59 day . All patient evaluate occurrence CDI AAD test accord local diagnostic standard monitor diarrhea ( 3 unformed stool per 24 hour period ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Clostridium Infections</mesh_term>
	<criteria>Expected minimum hospital stay 5 day Expected â‰¥5 day course intravenous ( IV ) ceftriaxone alone combination macrolide Clinical diagnosis moderate severe low respiratory tract infection consist sign symptom low respiratory tract infection Pneumonia Severity Index ( PSI/PORT ) score CAP 90130 , inclusive . Evidence new progressive infiltrate chest xray recommend . Presence diarrheal illness within 72 hour prior randomization Current treatment CDAD ongoing active CDI , evidence clinical sign diarrhea along presence toxin A and/or B ( respective gene , tcdA and/or tcdB ) C. difficile stool Number previous CDAD episode &gt; 1 within 12 week randomization C. difficile infection ( CDI ) within 4 week randomization Use antibiotic within 1 month start study drug except current illness .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>